NCT05165446
Novel MRE Technique to Assess a Risk Factor for Liver Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 9 versions: 7 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 36 words
- Study completion pushed from Aug 30, 2026 to Jan 30, 2027
- Minor Study completion date: Sep 30, 2025 to Aug 30, 2026v8
- Minor Primary completion date changed from estimate of Jan 2024 to Jan 1, 2024
- Study completion date: Mar 2024 to Sep 30, 2025
- Notable Primary completion date: Mar 2023 to Jan 2024
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: Mar 2023 to Mar 2024
- Site details revised
- Minor Primary and study completion dates: Jan 2023 to Mar 2023
- Site contact updated
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Jan 2022 to Jan 27, 2022
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Novel MRE technique to assess tissue viscoelasticity as a risk factor for liver cancer
Timeframe: For individual patients: duration of the study 8 weeks (including lab, scheduling the MR and 4w post MR period).
Secondary (1)
Studies on liver injury and glycemic control.
Sites
1 site in 1 country
- Stanford HospitalStanford, California, United States